請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/47687
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳青周 | |
dc.contributor.author | Chia-Chieh Lin | en |
dc.contributor.author | 林家潔 | zh_TW |
dc.date.accessioned | 2021-06-15T06:12:41Z | - |
dc.date.available | 2015-09-13 | |
dc.date.copyright | 2010-09-13 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-08-12 | |
dc.identifier.citation | Arias-Negrete, S., K. Keller, et al. (1995). 'Proinflammatory cytokines regulate cyclooxygenase-2 mRNA expression in human macrophages.' Biochem Biophys Res Commun 208(2): 582-589.
Barros, F. F., D. G. Powe, et al. (2010). 'Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments.' Histopathology 56(5): 560-572. Baselga, J. and S. M. Swain (2009). 'Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.' Nat Rev Cancer 9(7): 463-475. Bendell, J. C., S. M. Domchek, et al. (2003). 'Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.' Cancer 97(12): 2972-2977. Bender, L. B., R. Cao, et al. (2004). 'The MES-2/MES-3/MES-6 complex and regulation of histone H3 methylation in C. elegans.' Curr Biol 14(18): 1639-1643. Bernstein, B. E., T. S. Mikkelsen, et al. (2006). 'A bivalent chromatin structure marks key developmental genes in embryonic stem cells.' Cell 125(2): 315-326. Borchardt, R. T., B. T. Keller, et al. (1984). 'Neplanocin A. A potent inhibitor of S-adenosylhomocysteine hydrolase and of vaccinia virus multiplication in mouse L929 cells.' J Biol Chem 259(7): 4353-4358. Boyer, L. A., K. Plath, et al. (2006). 'Polycomb complexes repress developmental regulators in murine embryonic stem cells.' Nature 441(7091): 349-353. Bracken, A. P., N. Dietrich, et al. (2006). 'Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions.' Genes Dev 20(9): 1123-1136. Bracken, A. P. and K. Helin (2009). 'Polycomb group proteins: navigators of lineage pathways led astray in cancer.' Nat Rev Cancer 9(11): 773-784. Bracken, A. P., D. Pasini, et al. (2003). 'EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.' EMBO J 22(20): 5323-5335. Buchanan, F. G., D. Wang, et al. (2003). 'Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor.' J Biol Chem 278(37): 35451-35457. Cao, Q., J. Yu, et al. (2008). 'Repression of E-cadherin by the polycomb group protein EZH2 in cancer.' Oncogene 27(58): 7274-7284. Cao, R., L. Wang, et al. (2002). 'Role of histone H3 lysine 27 methylation in Polycomb-group silencing.' Science 298(5595): 1039-1043. Castelao, J. E., R. D. Bart, 3rd, et al. (2003). 'Lung cancer and cyclooxygenase-2.' Ann Thorac Surg 76(4): 1327-1335. Chang, Y. J., M. S. Wu, et al. (2005). 'Helicobacter pylori-Induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation.' J Immunol 175(12): 8242-8252. Chen, F. L., W. Xia, et al. (2008). 'Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.' Clin Cancer Res 14(21): 6730-6734. Chiang, P. K. (1998). 'Biological effects of inhibitors of S-adenosylhomocysteine hydrolase.' Pharmacol Ther 77(2): 115-134. Cobleigh, M. A., C. L. Vogel, et al. (1999). 'Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.' J Clin Oncol 17(9): 2639-2648. Cottu, P. H., J. Asselah, et al. (2008). 'Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer.' Ann Oncol 19(3): 595-597. Crofford, L. J. (1997). 'COX-1 and COX-2 tissue expression: implications and predictions.' J Rheumatol Suppl 49: 15-19. Delerive, P., K. De Bosscher, et al. (1999). 'Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1.' J Biol Chem 274(45): 32048-32054. Delerive, P., P. Gervois, et al. (2000). 'Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators.' J Biol Chem 275(47): 36703-36707. Dhillon, S. and A. J. Wagstaff (2007). 'Lapatinib.' Drugs 67(14): 2101-2108; discussion 2109-2110. Dormond, O., A. Foletti, et al. (2001). 'NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis.' Nat Med 7(9): 1041-1047. Ellis M.,Hayes D.,Lippman M.,Harris J.,Lippman M.,Morrow M.,Osborne C. (2000) Treatment of metastatic breast cancer Diseases of the Breast ,pp.749-797(2) Felsenfeld, G. and M. Groudine (2003). 'Controlling the double helix.' Nature 421(6921): 448-453. Fenwick, S. W., G. J. Toogood, et al. (2003). 'The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases.' Gastroenterology 125(3): 716-729. Finn, R. S., M. F. Press, et al. (2009). 'Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer.' J Clin Oncol 27(24): 3908-3915. Fiskus, W., Y. Wang, et al. (2009). 'Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.' Blood 114(13): 2733-2743. Gil, J., D. Bernard, et al. (2005). 'Role of polycomb group proteins in stem cell self-renewal and cancer.' DNA Cell Biol 24(2): 117-125. Gonzalez, M. E., X. Li, et al. (2009). 'Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1.' Oncogene 28(6): 843-853. Gril, B., D. Palmieri, et al. (2008). 'Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.' J Natl Cancer Inst 100(15): 1092-1103. Grunstein, M. (1990). 'Nucleosomes: regulators of transcription.' Trends Genet 6(12): 395-400. Guarneri, V., D. J. Lenihan, et al. (2006). 'Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.' J Clin Oncol 24(25): 4107-4115. Gupta, R. A. and R. N. Dubois (2001). 'Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.' Nat Rev Cancer 1(1): 11-21. Han, C., G. K. Michalopoulos, et al. (2006). 'Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells.' J Cell Physiol 207(1): 261-270. Hanna, W., S. Nofech-Mozes, et al. (2007). 'Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event.' Breast J 13(2): 122-129. Hayes, S. (2006). 'Pathways to silencing unite.' Nat Cell Biol 8(4): 315. Heard, E. (2005). 'Delving into the diversity of facultative heterochromatin: the epigenetics of the inactive X chromosome.' Curr Opin Genet Dev 15(5): 482-489. Herschman, H. R. (1996). 'Prostaglandin synthase 2.' Biochim Biophys Acta 1299(1): 125-140. Huang, W. C., J. J. Chen, et al. (2003). 'Tyrosine phosphorylation of I-kappa B kinase alpha/beta by protein kinase C-dependent c-Src activation is involved in TNF-alpha-induced cyclooxygenase-2 expression.' J Immunol 170(9): 4767-4775. Hudis, C. A. (2007). 'Trastuzumab--mechanism of action and use in clinical practice.' N Engl J Med 357(1): 39-51. Hurst, D. R., M. D. Edmonds, et al. (2009). 'Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis.' Cancer Res 69(4): 1279-1283. Inoue, H., C. Yokoyama, et al. (1995). 'Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element.' J Biol Chem 270(42): 24965-24971. Jackisch, C. (2006). 'HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy.' Oncologist 11 Suppl 1: 34-41. Kaidi, A., D. Qualtrough, et al. (2006). 'Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia.' Cancer Res 66(13): 6683-6691. Kamminga, L. M., L. V. Bystrykh, et al. (2006). 'The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion.' Blood 107(5): 2170-2179. Karim, S., A. Habib, et al. (1996). 'Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane.' J Biol Chem 271(20): 12042-12048. Kerppola, T. K. (2009). 'Polycomb group complexes--many combinations, many functions.' Trends Cell Biol 19(12): 692-704. Kirmizis, A., S. M. Bartley, et al. (2004). 'Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27.' Genes Dev 18(13): 1592-1605. Kleer, C. G., Q. Cao, et al. (2003). 'EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.' Proc Natl Acad Sci U S A 100(20): 11606-11611. Koninki, K., M. Tanner, et al. (2009). 'HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005.' Breast Cancer Res 11(3): R37. Kosaka, T., A. Miyata, et al. (1994). 'Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2.' Eur J Biochem 221(3): 889-897. Min, J., A. Zaslavsky, et al. (2010). 'An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB.' Nat Med 16(3): 286-294. Miranda, T. B., C. C. Cortez, et al. (2009). 'DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.' Mol Cancer Ther 8(6): 1579-1588. Muller, J., C. M. Hart, et al. (2002). 'Histone methyltransferase activity of a Drosophila Polycomb group repressor complex.' Cell 111(2): 197-208. Nahta, R., D. Yu, et al. (2006). 'Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.' Nat Clin Pract Oncol 3(5): 269-280. Okamoto, H., T. Iwamoto, et al. (2005). 'Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis.' Clin Exp Rheumatol 23(3): 323-330. Olayioye, M. A., R. M. Neve, et al. (2000). 'The ErbB signaling network: receptor heterodimerization in development and cancer.' EMBO J 19(13): 3159-3167. Otte, A. P. and T. H. Kwaks (2003). 'Gene repression by Polycomb group protein complexes: a distinct complex for every occasion?' Curr Opin Genet Dev 13(5): 448-454. Owen-Hughes, T. and J. L. Workman (1994). 'Experimental analysis of chromatin function in transcription control.' Crit Rev Eukaryot Gene Expr 4(4): 403-441. Pai, R., T. Nakamura, et al. (2003). 'Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors.' FASEB J 17(12): 1640-1647. Pairet, M. and G. Engelhardt (1996). 'Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications.' Fundam Clin Pharmacol 10(1): 1-17. Papewalis, J., A. Nikitin, et al. (1991). 'G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene.' Nucleic Acids Res 19(19): 5452. Parkin, D. M., F. Bray, et al. (2005). 'Global cancer statistics, 2002.' CA Cancer J Clin 55(2): 74-108. Piccart-Gebhart, M. J., M. Procter, et al. (2005). 'Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.' N Engl J Med 353(16): 1659-1672. Pien, S. and U. Grossniklaus (2007). 'Polycomb group and trithorax group proteins in Arabidopsis.' Biochim Biophys Acta 1769(5-6): 375-382. Pohlmann, P. R., I. A. Mayer, et al. (2009). 'Resistance to Trastuzumab in Breast Cancer.' Clin Cancer Res 15(24): 7479-7491. Ranger, G. S., V. Thomas, et al. (2004). 'Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer.' Anticancer Res 24(4): 2349-2351. Ristimaki, A., N. Honkanen, et al. (1997). 'Expression of cyclooxygenase-2 in human gastric carcinoma.' Cancer Res 57(7): 1276-1280. Sano, H., Y. Kawahito, et al. (1995). 'Expression of cyclooxygenase-1 and -2 in human colorectal cancer.' Cancer Res 55(17): 3785-3789. Schechter, A. L., D. F. Stern, et al. (1984). 'The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen.' Nature 312(5994): 513-516. Sheng, H., J. Shao, et al. (1998). 'Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells.' Cancer Res 58(2): 362-366. Simon, J. A. and C. A. Lange (2008). 'Roles of the EZH2 histone methyltransferase in cancer epigenetics.' Mutat Res 647(1-2): 21-29. Slamon, D. J., G. M. Clark, et al. (1987). 'Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.' Science 235(4785): 177-182. Tan, J., X. Yang, et al. (2007). 'Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells.' Genes Dev 21(9): 1050-1063. Tsai, Shing-Ling (2010). 'Lapatinib facilitates the migration of HER2neg/low breast cancer cells via EGFR/COX-2 overexpression in a miR-7-dependent manner.' Graduate Institute of Cancer Biology of China Medical University. Tsankova, N., W. Renthal, et al. (2007). 'Epigenetic regulation in psychiatric disorders.' Nat Rev Neurosci 8(5): 355-367. Tsuji, S., M. Tsujii, et al. (2001). 'Cyclooxygenase-2 upregulation as a perigenetic change in carcinogenesis.' J Exp Clin Cancer Res 20(1): 117-129. Tsujii, M. and R. N. DuBois (1995). 'Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2.' Cell 83(3): 493-501. Tsujii, M., S. Kawano, et al. (1997). 'Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential.' Proc Natl Acad Sci U S A 94(7): 3336-3340. Tsujii, M., S. Kawano, et al. (1998). 'Cyclooxygenase regulates angiogenesis induced by colon cancer cells.' Cell 93(5): 705-716. Tzahar, E., H. Waterman, et al. (1996). 'A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor.' Mol Cell Biol 16(10): 5276-5287. Valabrega, G., F. Montemurro, et al. (2007). 'Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.' Ann Oncol 18(6): 977-984. Vane, J. R., Y. S. Bakhle, et al. (1998). 'Cyclooxygenases 1 and 2.' Annu Rev Pharmacol Toxicol 38: 97-120. Varambally, S., S. M. Dhanasekaran, et al. (2002). 'The polycomb group protein EZH2 is involved in progression of prostate cancer.' Nature 419(6907): 624-629. Vire, E., C. Brenner, et al. (2006). 'The Polycomb group protein EZH2 directly controls DNA methylation.' Nature 439(7078): 871-874. Visser, H. P., M. J. Gunster, et al. (2001). 'The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma.' Br J Haematol 112(4): 950-958. Vogel, C. L., M. A. Cobleigh, et al. (2002). 'Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.' J Clin Oncol 20(3): 719-726. Wang, J., J. Mager, et al. (2002). 'The mouse PcG gene eed is required for Hox gene repression and extraembryonic development.' Mamm Genome 13(9): 493-503. Paul, B., J. A. Trovato, et al. (2008). 'Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer.' Am J Health Syst Pharm 65(18): 1703-1710. Pertschuk, L. P., C. A. Axiotis, et al. (1999). 'Marked Intratumoral Heterogeneity of the Proto-Oncogene Her-2/neu Determined by Three Different Detection Systems.' Breast J 5(6): 369-374. Puppe, J., R. Drost, et al. (2009). 'BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A.' Breast Cancer Res 11(4): R63. Rowinsky, E. K. (2004). 'The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors.' Annu Rev Med 55: 433-457. Santos-Rosa, H., R. Schneider, et al. (2002). 'Active genes are tri-methylated at K4 of histone H3.' Nature 419(6905): 407-411. Singh-Ranger, G., M. Salhab, et al. (2008). 'The role of cyclooxygenase-2 in breast cancer: review.' Breast Cancer Res Treat 109(2): 189-198. Slamon, D. J., W. Godolphin, et al. (1989). 'Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.' Science 244(4905): 707-712. Tanabe, T. and N. Tohnai (2002). 'Cyclooxygenase isozymes and their gene structures and expression.' Prostaglandins Other Lipid Mediat 68-69: 95-114. Webster, R. J., K. M. Giles, et al. (2009). 'Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7.' J Biol Chem 284(9): 5731-5741. Wicha, M. S. (2009). 'Development of 'synthetic lethal' strategies to target BRCA1-deficient breast cancer.' Breast Cancer Res 11(5): 108. Witton, C. J., J. R. Reeves, et al. (2003). 'Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.' J Pathol 200(3): 290-297. Xie, W., B. S. Fletcher, et al. (1994). 'v-src induction of the TIS10/PGS2 prostaglandin synthase gene is mediated by an ATF/CRE transcription response element.' Mol Cell Biol 14(10): 6531-6539. Yamamoto, T., S. Ikawa, et al. (1986). 'Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor.' Nature 319(6050): 230-234. Yu, J., Q. Cao, et al. (2007). 'Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer.' Cancer Cell 12(5): 419-431. Yu, J., D. R. Rhodes, et al. (2007). 'A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.' Cancer Res 67(22): 10657-10663. Zeidler, M., S. Varambally, et al. (2005). 'The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells.' Neoplasia 7(11): 1011-1019. Zimmermann, K. C., M. Sarbia, et al. (1999). 'Cyclooxygenase-2 expression in human esophageal carcinoma.' Cancer Res 59(1): 198-204. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/47687 | - |
dc.description.abstract | 乳癌是世界上相當普遍的癌症,20%~25%的乳癌之腫瘤會過度表現HER2,此oncoprotein屬於EGFR family,其表現量與癌症之惡性、轉移及較差的存活率相關。Herceptin為最早上市之HER2標靶藥物,可有效延長HER2陽性病患之存活率,Lapatinib為新一代之HER2標靶藥物,為EGFR/HER2之酪胺酸激酶抑制劑,能治療以化療合併Hercetin失敗之乳癌病患,但治療數月後亦會對藥物產生抗藥性而導致腫瘤之復發。IHC之分析發現,HER2陽性之腫瘤內並非均質狀態,HER2陰性之癌細胞雖佔少數,但因不受HER2標靶藥物所抑制,有可能成為日後癌症復發或轉移之來源,先前之研究發現MDA-MB-231此株HER2low/neg細胞長期處理lapatinib後產生之231/lap細胞,其移動及侵入能力顯著上升,顯示lapatinib雖可抑制HER2陽性癌細胞,但也可能惡化HER2陰性癌細胞(Tsai, Shing-Ling 2010)。已知231/lap細胞之COX-2表現有EGFR及p-ERK之參與,我們發現231/lap細胞之EZH2表現較高,且EZH2會增加COX-2之表現,藉由lenti-virus或DZNep抑制EZH2皆可抑制COX-2而降低轉移及侵入,我們也發現DZNep除能抑制EZH2外,也可抑制EGFR之表現及ERK之磷酸化,並且造成cycle arrest及apoptosis,顯示DZNep對這些細胞有治療潛力,因此HER2陽性病患之治療,除了使用lapatinb抑制HER2陽性癌細胞之外,應併用DZNep防止腫瘤內HER2陰性癌細胞之轉移及侵入,以達到更好的抑癌效果。 | zh_TW |
dc.description.abstract | Breast cancer is a very common cancer around the world and overexpression of HER2 is found in 20-25% of the patients. HER2 is a oncoprotein belongs to EGFR family, and its expression level was associated with advanced disease stage, metastasis and poor survival. Herceptin is the first approved monoclonal antibody for HER2-target therapy, and can effectively prolong the survival of HER2-positive patients. Lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor, is a newly small molecule for patients who had received prior chemotherapy and Herceptin. However, there were still patients occurring drug resistance after several months of lapatinib treatment and resulting in tumor recurrence. HER-positive tumors showed heterogenous HER2 expression in IHC analysis, and minor subpopulation of HER2-negative cells may escape from HER2 targeting drugs and may be the seeds for tumor recurrence and metastasis. HER2-negative MDA-MB-231 cells were chronically treated with lapatinib, and MDA-MB-231 (231/lap) clones were derived. These clones show higher migration and invasion abilities due to the overexpression of COX-2, indicating that lapatinib might enhance the aggressiveness of HER2-negative cells during its treatment on HER2-positive breast cancer patients (Tsai, Shing-Ling 2010). EGFR expression and ERK phosphorylation were found to be involved in COX-2 overexpression of 231/lap cells. Here we found that EZH2 was upregulated in 231/lap clones. Lenti-viral shEZH2 to knockdown EZH2 or an EZH2 inhibitor-DZNep effectively decreased COX-2 expression and cell migration and invasion. DZNep could also inhibit EGFR expression and ERK phsphorylation, and induce cell cycle arrest and apoptosis. To improve the outcomes, we suggest that HER2-positive cancer patients who received lapatinib should co-treat with DZNep to reduce the metastasis and recurrence by the HER2-negative cancer cells. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T06:12:41Z (GMT). No. of bitstreams: 1 ntu-99-R97443007-1.pdf: 4377314 bytes, checksum: d5ab2115164d8248d4bbb90d73a4b353 (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 縮寫表 (Abbreviations)........................................................................2
中文摘要 (Abstract in Chinese)..........................................................4 英文摘要 (Abstract in English)...........................................................6 第一章、 緒論(Introduction)..............................................................8 第一節、 ERBB 家族 / HER家族................................................9 第二節、 HER2及乳癌..................................................................13 第三節、 Chromatin remodeling及EZH2...................................23 第四節、 EZH2與癌症的相關性.................................................30 第五節、 EZH2抑制劑:DZNep.................................................35 第六節、 COX-2與metastasis及invasion的相關性................37 研究動機............................................................................................42 第二章、 實驗材料與方法 (Materials and Methods).....................43 第三章、結果 (Results)......................................................................56 第四章、討論 (Discussion)................................................................84 第五章、結論與未來展望 (Conclusions and Perspectives)................89 參考文獻 (References)........................................................................92 | |
dc.language.iso | zh-TW | |
dc.title | EZH2 inhibitors在lapatinib處理之HER2low/neg乳癌細胞抑制轉移作用之探討 | zh_TW |
dc.title | EZH2 inhibitors suppress migration of lapatinib-treated HER2low/neg breast cancer cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 吳明賢,黃偉謙 | |
dc.subject.keyword | 乳癌,轉移,標靶藥物,人類表皮生長因子受體, | zh_TW |
dc.subject.keyword | breast cancer,HER2,lapatinib,EZH2,DZNep, | en |
dc.relation.page | 100 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2010-08-13 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 4.27 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。